Context: Diabetes mellitus is a risk factor for nephrolithiasis. A recent observational study found that in patients with type 2 diabetes (T2D), SGLT2 inhibitor use was associated with a 49% lower risk of nephrolithiasis compared with GLP-1 receptor agonists. Objective: We examined the association between nephrolithiasis and the SGLT2 inhibitor empagliflozin, using existing data from … Leggi tutto
… This post hoc analysis shows that SGLT2i may reduce kidney calciumcontaining stone risk by decreasing the RSR of CaP minerals in healthy subjects. This effect seems to be mediated by increased urinary citrate and reduced urinary pH. Prospective trials with kidney stone formers are needed to evaluate the effect of SGLT2i in secondary prevention of nephrolithiasis.
… Results We identified 24,290 and 19,576 eligible users of SGLT2Is and GLP1 RAs, respectively. After matching, 12,325 patient pairs remained. The median age was 61 years and median follow-up was 2.0 years. The nephrolithiasis rate was 2.0 per 1000 person-years in SGLT2I initiators compared with 4.0 per 1000 person-years in GLP1 RA initiators, with a rate … Leggi tutto